This session examines the growing global experience in the treatment of calcified coronary lesions, bringing together updated clinical evidence and real-world practice.

Recent data are discussed alongside insights from high-volume operators to show how calcium modification strategies are evolving and being integrated into contemporary PCI workflows.

By combining...

Renal denervation is re-emerging as a valuable therapeutic option for selected patients with hypertension.

This session explores how current evidence, consensus statements, and guidelines inform patient selection for ultrasound renal denervation, while providing practical insight into how the procedure is performed in daily practice.

Beyond the technical aspects,...

At TCT 2019 in San Francisco - USA, Robert-Jan Van Geuns presented the results of the IDEAL-LM trial. Read the analysis by Christopher Cook.

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022. 

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...